📊 ANTX Key Takeaways
Is AN2 Therapeutics, Inc. (ANTX) a Good Investment?
AN2 is a pre-revenue biopharmaceutical company with a strong balance sheet ($53.5M cash, zero debt) but severe execution risks. With $12.1M annual cash burn and no revenue, the company has approximately 4-5 years of runway before capital exhaustion. Without visibility into clinical pipeline success or near-term revenue catalysts, the fundamental risk profile of early-stage drug development outweighs financial strength.
AN2 Therapeutics remains a pre-revenue biotechnology company with no commercial income and substantial recurring losses, which makes the fundamental profile highly dependent on cash consumption rather than operating performance. The balance sheet is currently clean, with strong liquidity and no long-term debt, but negative operating cash flow of nearly $30M against roughly $20M of cash suggests funding risk unless spending falls materially or new capital is raised. Profitability trends are still weak despite EPS improvement, because the business has not yet demonstrated revenue generation or self-sustaining growth quality.
AN2 Therapeutics, Inc. Key Strengths (ANTX)
- Strong cash position of $53.5M with 15.73x current ratio providing operational flexibility
- Zero debt and healthy equity base of $81.8M with liabilities only $5.7M
- Intact capital structure allows extended runway for clinical development programs
- Strong short-term liquidity with a 6.87x current and quick ratio
- Debt-free capital structure reduces financial leverage risk
- Equity base remains positive at $53.06M, providing some balance sheet cushion
ANTX Stock Risks: AN2 Therapeutics, Inc. Investment Risks
- Pre-revenue company with no product sales or demonstrated commercial viability
- Annual cash burn of $12.1M limits runway to 4-5 years without additional funding
- Typical biopharmaceutical failure risk with clinical-stage pipeline requiring successful regulatory approval
- Operating losses of $10.6M indicate heavy R&D spending with no offsetting revenue
- Limited disclosure on pipeline maturity, clinical trial status, or regulatory pathway clarity
- No revenue base, making the company entirely reliant on external financing and pipeline execution
- Large net loss and negative operating cash flow indicate an unsustainable standalone operating model
- Cash balance of $19.94M versus $29.83M annual operating cash burn implies limited runway
Key Metrics to Watch
- Cash burn rate trend and extension through partnerships or additional financing
- Clinical trial advancement milestones and regulatory feedback for lead candidates
- Path to revenue through product approvals, licensing deals, or strategic collaborations
- Quarterly operating cash burn relative to cash and equivalents
- Any emergence of collaboration, licensing, or product revenue that validates growth quality
AN2 Therapeutics, Inc. (ANTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.73x current ratio provides a solid financial cushion.
ANTX Profit Margin, ROE & Profitability Analysis
ANTX vs Healthcare Sector: How AN2 Therapeutics, Inc. Compares
How AN2 Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AN2 Therapeutics, Inc. Stock Overvalued? ANTX Valuation Analysis 2026
Based on fundamental analysis, AN2 Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AN2 Therapeutics, Inc. Balance Sheet: ANTX Debt, Cash & Liquidity
ANTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AN2 Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
ANTX Revenue Growth, EPS Growth & YoY Performance
AN2 Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ANTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AN2 Therapeutics, Inc. (CIK: 0001880438)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANTX
What is the AI rating for ANTX?
AN2 Therapeutics, Inc. (ANTX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANTX's key strengths?
Claude: Strong cash position of $53.5M with 15.73x current ratio providing operational flexibility. Zero debt and healthy equity base of $81.8M with liabilities only $5.7M. ChatGPT: Strong short-term liquidity with a 6.87x current and quick ratio. Debt-free capital structure reduces financial leverage risk.
What are the risks of investing in ANTX?
Claude: Pre-revenue company with no product sales or demonstrated commercial viability. Annual cash burn of $12.1M limits runway to 4-5 years without additional funding. ChatGPT: No revenue base, making the company entirely reliant on external financing and pipeline execution. Large net loss and negative operating cash flow indicate an unsustainable standalone operating model.
What is ANTX's revenue and growth?
AN2 Therapeutics, Inc. reported revenue of N/A.
Does ANTX pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
Where can I find ANTX SEC filings?
Official SEC filings for AN2 Therapeutics, Inc. (CIK: 0001880438) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANTX's EPS?
AN2 Therapeutics, Inc. has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ANTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, AN2 Therapeutics, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ANTX stock overvalued or undervalued?
Valuation metrics for ANTX: ROE of -12.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ANTX's AI grade for 2026?
Our dual AI analysis gives AN2 Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANTX's free cash flow?
AN2 Therapeutics, Inc.'s operating cash flow is $-12.1M, with capital expenditures of N/A.
How does ANTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -12.3% (avg: 15%), current ratio 15.73 (avg: 2).